Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging

Dementia and Geriatric Cognitive Disorders

Volumn 30, Issue 1, 2010, Pages 71-77

  Watanabe, Toshiyuki ^a,b   Shiino, Akihiko ^b   Akiguchi, Ichiro ^a,c  

^a Ujitakeda Hospital   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c Takeda Hospital   (Japan)

Author keywords

Alzheimer's disease; Amnesic mild cognitive impairment; Choline compounds; N acetylaspartate; Proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMNESIA; AMNESIC MILD COGNITIVE IMPAIRMENT; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIPPOCAMPUS; HUMAN; MALE; METABOLITE; MILD COGNITIVE IMPAIRMENT; OCCIPITAL LOBE; OUTCOME ASSESSMENT; POSTERIOR PERIVENTRICULAR AND DEEP WHITE MATTERS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

AGED; AGING; ALZHEIMER DISEASE; AMNESIA; ANALYSIS OF VARIANCE; ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CHOLINE; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES;

EID: 77955122149     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318750     Document Type: Article

References (39)

1. Grundman M, Petersen RC, Ferris SH, Thomas RG, Alsen PS, Bennet DA, et al: Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004; 61: 59-66.
2. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60: 1374-1377.
3. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-1113.
4. Kantarci K, Jack CR, Xu YC, Campeau NG, O'Brien PC, Smith GE, et al: Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1 H MRS study. Neurology 2000; 25: 210-217.
5. Kantarci K, Xu YC, Shiung MM, O'Brien PC, Cha RH, Smith GE, et al: Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dementia Geriatr Cogn Disord 2002; 14: 198-207.
6. Kantarci K, Reynolds G, Xu YC, Petersen RC, Boeve BF, Knopman D, et al: Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3T. AJNR Am J Neuroradiol 2003; 24: 843-849.
7. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, et al: 1 H MR spectroscopy in common dementias. Neurology 2004; 63: 1393-1398.
8. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, et al: Longitudinal H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2006; 28: 1330-1339.
9. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, et al: Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1 H MRS. Neurology 2009; 72: 1519-1525.
10. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, Piccirilli M, et al: 1 H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2003; 12: 2315-2317.
11. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y: Similar 1 H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004; 1003: 26-35.
12. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, Molla E, Celda B: Cognitive impairment: classification by 1 H magnetic resonance spectroscopy. Eur J Neurol 2004; 11: 187-193.
13. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer D: Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2005; 384: 23-28.
14. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, et al: Reduced medial temporal lobe N-acetylaspartate in cognitively impaired nondemented patients. Neurology 2005; 64: 282-289.
15. Falini A, Bozzali M, Magnani G, Pero G, Gambini A, Benedetti B, et al: A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 2005; 26: 1159-1163.
16. Modrego PJ, Fayed N, Pina MA: Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005; 162: 667-675.
17. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, et al: Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006; 27: 926-932.
18. Perneczky R, Hartmann J, Grimmer T, Drzezga A, Kurz A: Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol 2007; 20: 84-88.
19. Garcia Santos JM, Gavrilla D, Antunez C, Tormo MJ, Salmeron D, Carles R, et al: Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. Dementia Geriatr Cogn Disord 2008; 26: 15-25.
20. Jessen F, Gur O, Block W, Ende G, Frolich L, Hammen T, et al: A multicenter 1 H-MRS study of the medial temporal lobe in AD and MCI. Neurology 2009; 72: 1735-1740.
21. Zhang B, Li M, Sun ZZ, Zhu B, Yuan L, Wang Y, et al: Evaluation of functional MRI markers in mild cognitive impairment. J Clin Neurosci 2009; 16: 635-641.
22. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R: Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2009, E-pub ahead of print.
23. Valenzuela MJ, Sachdev P: Magnetic resonance spectroscopy in Alzheimer's disease. Neurology 2001; 56: 592-598.
24. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA: N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131.
25. Watanabe T, Akiguchi I, Yagi H, Onishi K, Kawasaki T, Shiino A, et al: Proton magnetic resonance spectroscopy and white matter hyperintensities on magnetic resonance imaging in patients with Alzheimer's disease. Ann NY Acad Sci 2002; 977: 423-429.
26. Watanabe T, Shiino A, Akiguchi I: Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease. Dement Geriatr Cogn Disord 2008; 26: 89-100.
27. Provencher SW: Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-679.
28. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
30. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
31. Folstein MF: Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
32. Shinagawa F, Kobayashi S, Fujita K, Maekawa H: Japanese Wechsler Adult Intelligence Scale Revised (in Japanese). Tokyo, Nihon Bunka Kagakusha, 1990.
33. Sugishita M: Japanese Wechsler Memory Scale Revised (in Japanese). Tokyo, Nihon Bunka Kagakusha, 2001.
34. Kreis R, Ernst T, Ross BD: Absolute quantification of water and metabolites in the human brain. 2. Metabolite concentrations. J Magn Reson Ser B 1993; 102: 9-19.
35. Choi CG, Frahm J: Localized proton MRS of the human hippocampus: metabolite concentrations and relaxation times. Magn Reson Med 1999; 41: 204-207.
36. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, et al: Proton MR spectroscopy detects a relative decrease of Nacetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000; 55: 684-688.
37. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al: Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD. Neurology 2001; 57: 930-932.
38. Franczak M, Prost RW, Antuouno PG, Mark LP, Jones JL, Ulmer JL: Proton magnetic resonance spectroscopy of the hippocampus in patients with mild cognitive impairment: a pilot study. J Comp Assist Tomogr 2007; 31: 666-670.
39. Wang XC, Du XX, Tian Q, Wang JZ: Correlation between choline signal intensity and acetylcholine level in different brain regions of rat. Neurochem Res 2008; 33: 814-819.